Biogen Inc. (BIIB)

Biogen Cash Flow Statement

Financials in millions USD. Fiscal year is January - December.

Year Ending	TTM	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019
Net Income	1,167	1,161	3,047	1,556	4,001	5,889
Depreciation & Amortization	530	494.8	638	1,117	666.9	680.6
Share-Based Compensation	261.4	264.2	254.1	238.6	198.3	182.3
Other Operating Activities	-312.9	-372.9	-2,554.7	728.2	-636	327.2
Operating Cash Flow	1,645	1,547	1,384	3,640	4,230	7,079
Operating Cash Flow Growth	-1.95%	11.77%	-61.97%	-13.95%	-40.25%	14.40%
Capital Expenditures	-360.7	-311.4	339.4	-276.9	-476.8	-669.5
Acquisitions	-6,138	-6,138	990.3	28.1	-1,006.5	-120.7
Change in Investments	3,296	2,360	222.5	-309.8	976.6	1,234
Other Investing Activities	-11.3	-11.3	24.4	-5.1	-101.9	27
Investing Cash Flow	-3,214	-4,101	1,577	-563.7	-608.6	470.5
Share Issuance / Repurchase	0	0	-750	-1,800	-6,679.1	-5,868.3
Debt Issued / Paid	-212.7	187.3	-1,002.2	-170	1,467	0
Other Financing Activities	-34.2	-38	4.9	-116.2	-61	7.9
Financing Cash Flow	-246.9	149.3	-1,747.3	-2,086.2	-5,272.7	-5,860.4
Exchange Rate Effect	-8	35.1	-55.7	-59.8	69	0.4
Net Cash Flow	-1,815.8	-2,404.5	1,214	990	-1,651.5	1,689
Free Cash Flow	1,284	1,236	1,724	3,363	3,753	6,409
Free Cash Flow Growth	-35.89%	-28.31%	-48.75%	-10.39%	-41.44%	18.38%
Free Cash Flow Margin	13.29%	12.56%	16.94%	30.62%	27.91%	44.58%
Free Cash Flow Per Share	8.85	8.54	11.86	22.55	23.32	34.26

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).